TUCSON, Ariz., Feb. 11, 2014 /PRNewswire/ -- Turkiye Yuksek Ihtisas Hospital in Ankara recently implanted Turkey's 24th and 25th SynCardia temporary Total Artificial Hearts as a bridge to transplant to donor human hearts.
One of the patients was discharged Jan. 31, 2014, less than six weeks following his Dec. 23, 2013 implant of the SynCardia Total Artificial Heart. He was able to leave the hospital because of the Freedom® portable driver, a 6-kilo wearable power supply that greatly increases patients' mobility and allows patients to exercise, eat and sleep at home and enjoy their community. This helps patients get stronger for their heart transplants.
"This patient was very sick with ischemic cardiomyopathy," says surgeon Dr. Umit Kervan, who performed the operation with surgeon Dr. Mustafa Pac. "The SynCardia Total Artificial Heart saved his life and the Freedom portable driver gives him almost unlimited mobility so he can exercise and get stronger for his second chance at life following his heart transplant."
As the Turkish distributor for the SynCardia Total Artificial Heart, Ufuk Yaranli, President and CEO of Natura Medikal Urunler Ltd., actively identifies and recruits the country's most talented cardiac surgeons and medical centers to become SynCardia Certified Centers.
"We have been fortunate that Turkey's best medical centers are implanting the Total Artificial Heart, which is the only device that eliminates the source and symptoms of end-stage biventricular heart failure," Mr. Yaranli says. "The SynCardia Heart has become the standard of care for this deadly heart disease. I'm also thankful to our well-trained Natura Clinical Support Team that does a great job in supporting patients throughout the implant process."
Like a human heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. The electronics that operate the SynCardia Heart are safely located outside of the body in the Freedom portable driver, which powers the SynCardia Heart with precisely calibrated pulses of air and vacuum.
Ege University in Izmir performed the first SynCardia Heart implant in Turkey on Sept. 30, 2010. Today there are nine SynCardia hospitals in Turkey, part of the network of 97 SynCardia Centers worldwide with an additional 39 heart hospitals in the process of certification.
The most recent SynCardia implant at Turkiye Yuksek Ihtisas Hospital was performed on Jan. 13, 2014. Other Turkish SynCardia Heart patients include
- a man who has been on the SynCardia Total Artificial Heart for nearly three-and-a-half years,
- then 17-year-old Yusuf Enec, and
- a 57-year-old former professional soccer player.
SynCardia recognizes and thanks Ufuk Yaranli and Natura Medikal Urunler Ltd., the Turkish distributor for the SynCardia Total Artificial Heart, for their commitment and on-going support of Turkish heart hospitals.
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,260 implants of the Total Artificial Heart, accounting for more than 350 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.
SOURCE SynCardia Systems, Inc.